FibroBiologics Inc
Filed Jun 18, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Jun 18, 2024
FBLG$0.98+2.4%Stored close · as of Nov 6, 2026
Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
| ● | the timing, progress and results of preclinical studies and clinical trials for our current and future product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; |
| ● | the timing, scope or likelihood of regulatory submissions, filings, and approvals, including final regulatory approval of our product candidates; |
| ● | our ability to develop and advance product candidates into, and successfully complete, clinical trials; |
| ● | the implementation of our business model and our strategic plans for our business, product candidates and technology; |
| ● | the rate and degree of market acceptance and clinical utility of our product candidates, in particular, and cell therapy, in general; |
| ● | our competitive position; |
| ● | the scope of protection we and/or our licensors are able to establish and maintain for intellectual property rights covering our product candidates; |
| ● | the impact of laws and regulations. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.